[96a5a0]: / output / allTrials / identified / NCT02009631_identified.json

Download this file

397 lines (397 with data), 17.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
{
"info": {
"nct_id": "NCT02009631",
"official_title": "A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors",
"inclusion_criteria": "* Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective.\n* Subjects with brain metastases must have clinically controlled neurologic symptoms.\n* Subject is able to swallow and retain oral medications and does not have uncontrolled emesis.\n* Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
"exclusion_criteria": "* Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia.\n* Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.\n* Subject has a history of cardiac conduction abnormalities.\n* Subject has a significant history of cardiovascular disease.\n* Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy.\n* Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose.\n* Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Confirmed solid malignancy that is metastatic or unresectable for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective.",
"criterions": [
{
"exact_snippets": "Confirmed solid malignancy",
"criterion": "solid malignancy",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"exact_snippets": "metastatic or unresectable",
"criterion": "malignancy status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"metastatic",
"unresectable"
]
}
]
},
{
"exact_snippets": "standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective",
"criterion": "availability of effective therapy",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
}
]
},
{
"line": "* Subjects with brain metastases must have clinically controlled neurologic symptoms.",
"criterions": [
{
"exact_snippets": "Subjects with brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clinically controlled neurologic symptoms",
"criterion": "neurologic symptoms",
"requirements": [
{
"requirement_type": "control status",
"expected_value": "clinically controlled"
}
]
}
]
},
{
"line": "* Subject is able to swallow and retain oral medications and does not have uncontrolled emesis.",
"criterions": [
{
"exact_snippets": "Subject is able to swallow and retain oral medications",
"criterion": "ability to swallow and retain oral medications",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "does not have uncontrolled emesis",
"criterion": "uncontrolled emesis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Subject has adequate bone marrow, renal and hepatic function per local laboratory reference ranges.",
"criterions": [
{
"exact_snippets": "adequate bone marrow ... per local laboratory reference ranges",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": "per local laboratory reference ranges"
}
]
},
{
"exact_snippets": "adequate ... renal ... function per local laboratory reference ranges",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": "per local laboratory reference ranges"
}
]
},
{
"exact_snippets": "adequate ... hepatic function per local laboratory reference ranges",
"criterion": "hepatic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": "per local laboratory reference ranges"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 99 Years",
"criterions": [
{
"exact_snippets": "maximum age of 99 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 99,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Subject has severe ECG morphologic abnormalities that make QTc evaluation difficult.",
"criterions": [
{
"exact_snippets": "severe ECG morphologic abnormalities",
"criterion": "ECG morphologic abnormalities",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "make QTc evaluation difficult",
"criterion": "QTc evaluation",
"requirements": [
{
"requirement_type": "difficulty",
"expected_value": true
}
]
}
]
},
{
"line": "* Subject has a history of cardiac conduction abnormalities.",
"criterions": [
{
"exact_snippets": "history of cardiac conduction abnormalities",
"criterion": "cardiac conduction abnormalities",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Subject has a significant history of cardiovascular disease.",
"criterions": [
{
"exact_snippets": "significant history of cardiovascular disease",
"criterion": "cardiovascular disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": "significant"
}
]
}
]
},
{
"line": "* Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug, or has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy.",
"criterions": [
{
"exact_snippets": "Subject has received any anti-cancer therapies 21 days prior to the first dose of study drug",
"criterion": "anti-cancer therapies",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "days"
}
}
]
},
{
"exact_snippets": "has recovered to no better than a grade 2 or higher clinically significant adverse effect(s)/toxicity(s) of the previous therapy",
"criterion": "adverse effect(s)/toxicity(s) of the previous therapy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "grade"
}
}
]
}
]
},
{
"line": "* Use of drugs with a known risk for QT prolongation and Torsades de Pointes within 7 days prior to the first study dose.",
"criterions": [
{
"exact_snippets": "Use of drugs with a known risk for QT prolongation",
"criterion": "use of drugs with a known risk for QT prolongation",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": "within 7 days prior to the first study dose"
}
]
},
{
"exact_snippets": "Use of drugs with a known risk for ... Torsades de Pointes",
"criterion": "use of drugs with a known risk for Torsades de Pointes",
"requirements": [
{
"requirement_type": "timeframe",
"expected_value": "within 7 days prior to the first study dose"
}
]
}
]
},
{
"line": "* Use of tobacco or nicotine-containing products within 12 hours prior to the first study dose.",
"criterions": [
{
"exact_snippets": "Use of tobacco or nicotine-containing products",
"criterion": "tobacco or nicotine use",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "within 12 hours prior to the first study dose"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* Uncorrected serum potassium, serum magnesium, serum calcium or free thyroxin (FT4) and thyroid stimulating hormone (TSH) outside of normal reference ranges, or grade 2 hyponatremia or hypernatremia.",
"criterions": [
{
"exact_snippets": "Uncorrected serum potassium ... outside of normal reference ranges",
"criterion": "serum potassium",
"requirements": [
{
"requirement_type": "range",
"expected_value": "outside of normal reference ranges"
}
]
},
{
"exact_snippets": "Uncorrected serum magnesium ... outside of normal reference ranges",
"criterion": "serum magnesium",
"requirements": [
{
"requirement_type": "range",
"expected_value": "outside of normal reference ranges"
}
]
},
{
"exact_snippets": "Uncorrected serum calcium ... outside of normal reference ranges",
"criterion": "serum calcium",
"requirements": [
{
"requirement_type": "range",
"expected_value": "outside of normal reference ranges"
}
]
},
{
"exact_snippets": "Uncorrected ... free thyroxin (FT4) ... outside of normal reference ranges",
"criterion": "free thyroxin (FT4)",
"requirements": [
{
"requirement_type": "range",
"expected_value": "outside of normal reference ranges"
}
]
},
{
"exact_snippets": "Uncorrected ... thyroid stimulating hormone (TSH) outside of normal reference ranges",
"criterion": "thyroid stimulating hormone (TSH)",
"requirements": [
{
"requirement_type": "range",
"expected_value": "outside of normal reference ranges"
}
]
},
{
"exact_snippets": "grade 2 hyponatremia",
"criterion": "hyponatremia",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "grade 2"
}
]
},
{
"exact_snippets": "grade 2 ... hypernatremia",
"criterion": "hypernatremia",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "grade 2"
}
]
}
]
}
],
"failed_miscellaneous": []
}